AVANOS MEDICAL, INC.(AVNS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,319 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AVNS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for AVANOS MEDICAL, INC. (AVNS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVNS at 31.3/100 on a 32-signal composite quality model, placing it at rank #2,319 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (3.9) and profitability (19.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 43.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AVANOS MEDICAL, INC. reports quarterly revenue of $182.2M, net income of $5.1M, free cash flow of $-16.6M. Top institutional holders of AVNS by reported 13-F value include BlackRock,, BROWN ADVISORY, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. AVNS trades on the NYSE exchange and files with the SEC under CIK 1606498. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVNS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AVANOS MEDICAL, INC. directly from SEC EDGAR. AVANOS MEDICAL, INC.'s 13F Pro composite quality score has ranged between 27 and 49 since 2021, currently 31.3 — a declining long-term trajectory across 30 quarterly and live scoring snapshots.
Revenue
Q1 2026
$182.2M
Net Income
Q1 2026
$5.1M
Free Cash Flow
Q1 2026
$-16.6M
D/E Ratio
Q1 2026
0.13
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-1.6% YoYNet Income
-222.4% YoYOperating Income
-88.2% YoYEPS (Diluted)
-223.4% YoYTotal Assets
-5.3% YoYTotal Debt
-27.7% YoYOp. Cash Flow
-64.4% YoY| Metric | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $673.3M -1.6% | $684.1M -4.3% | $714.8M +2.5% | $697.6M +6.9% | $652.3M +15.2% | $566.2M |
| Net Income | $-61.8M -222.4% | $50.5M +274.1% | $-29.0M +36.8% | $-45.9M -179.8% | $57.5M +44.5% | $39.8M |
| Operating Income | $4.2M -88.2% | $35.5M +173.2% | $-48.5M +12.9% | $-55.7M -11240.0% | $500.0K +100.5% | $-107.1M |
| EPS (Diluted) | $-1.32 -223.4% | $1.07 +275.4% | $-0.61 +36.5% | $-0.96 -178.7% | $1.22 +43.5% | $0.85 |
| Total Assets | $1.69B -5.3% | $1.79B +6.8% | $1.67B -7.0% | $1.80B -1.8% | $1.83B -11.5% | $2.07B |
| Total Debt | $168.0M -27.7% | $232.5M +29.2% | $180.0M -27.4% | $248.1M +0.2% | $247.7M -57.2% | $579.0M |
| Operating Cash Flow | $32.4M -64.4% | $90.9M +3736.0% | $-2.5M +96.6% | $-74.5M +48.8% | $-145.6M -177.1% | $188.8M |
Get alerted when AVNS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for AVANOS MEDICAL, INC. including:
Top Institutional Holders of AVNS
BlackRock, Inc.
$95.9M6,843,733 shBROWN ADVISORY INC
$31.3M2,231,198 shDIMENSIONAL FUND ADVISORS LP
$28.8M2,052,356 shARMISTICE CAPITAL, LLC
$28.0M2,000,000 shSTATE STREET CORP
$27.6M1,972,523 shVANGUARD CAPITAL MANAGEMENT LLC
$27.6M1,971,965 shVANGUARD PORTFOLIO MANAGEMENT LLC
$17.4M1,239,295 shBOONE CAPITAL MANAGEMENT LLC
$16.6M1,184,909 shGEODE CAPITAL MANAGEMENT, LLC
$15.3M1,094,235 shCHARLES SCHWAB INVESTMENT MANAGEMENT INC
$14.8M1,058,066 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $95.9M | 6,843,733 |
| BROWN ADVISORY INC | $31.3M | 2,231,198 |
| DIMENSIONAL FUND ADVISORS LP | $28.8M | 2,052,356 |
| ARMISTICE CAPITAL, LLC | $28.0M | 2,000,000 |
| STATE STREET CORP | $27.6M | 1,972,523 |
| VANGUARD CAPITAL MANAGEMENT LLC | $27.6M | 1,971,965 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $17.4M | 1,239,295 |
| BOONE CAPITAL MANAGEMENT LLC | $16.6M | 1,184,909 |
| GEODE CAPITAL MANAGEMENT, LLC | $15.3M | 1,094,235 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $14.8M | 1,058,066 |
More Healthcare Companies
View all Healthcare →Put AVNS on your watchlist
Track score changes the day AVANOS MEDICAL, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AVNS a good stock to buy?
13F Pro's AI-powered analysis of AVANOS MEDICAL, INC. (AVNS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVNS are available on the AVNS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AVNS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVNS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AVANOS MEDICAL, INC.'s investment landscape.